ArticleDevelopment (Cambridge, England)2026
Loss of arap3 drives a cerebral cavernous malformation-like phenotype in zebrafish via Krit1 interaction and RhoA dysregulation.
Article in Development (Cambridge, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cerebral cavernous malformations (CCMs) are severe vascular anomalies characterized by abnormal cerebrovascular development, leading to profound structural and functional deficits in the brain. However, the exact underlying mechanisms driving CCM pathogenesis remain incompletely understood. In this study, we identify a zebrafish arap3 mutant that exhibits localized vascular dilation, cerebral hemorrhage, impaired vascular network formation and reduced mural cell coverage - phenotypes that collectively and strikingly recapitulate the key pathological features of clinical CCM. We demonstrate that arap3 is highly enriched in cerebrovascular endothelial cells, and its deficiency severely impairs endothelial cell polarity and overall vascular homeostasis. Mechanistically, arap3 contributes to CCM pathogenesis through the dysregulation of RhoA GTPase activity. Furthermore, we provide compelling evidence physically and functionally linking Arap3 to the CCM signaling complex by demonstrating that Arap3 interacts with Krit1 (CCM1). Our findings establish a crucial framework for understanding the etiology of CCM and present a highly trackable in vivo model for the future discovery of targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.